Isfahan University of Medical Sciences Reports Findings in Tuberous Sclerosis (Efficacy and Safety of Topical Timolol for the Treatment of Facial Angiofibroma in Children with Tuberous Sclerosis Complex).

A study conducted by researchers at Isfahan University of Medical Sciences in Iran examined the efficacy and safety of topical timolol in treating facial angiofibromas (FAs) in pediatric patients with tuberous sclerosis complex (TSC). The study involved 15 children diagnosed with TSC and presenting with FAs. The participants were administered topical timolol gel 0.5% twice daily, and the severity of FAs was evaluated using the FA severity index (FASI). The results showed statistically significant reductions in the mean FASI score, erythema, size, and extent of lesions after discontinuing topical timolol. The study concluded that topical timolol 0.5% is a cost-effective and readily available treatment option for pediatric patients with FAs associated with tuberous sclerosis. [Extracted from the article]